Patients receiving fulvestrant experienced a higher incidence of grade ≥ 3 hematologic adverse events (59% vs. 48%, p = 0.174) and grade ≥ 3 neutropenia (57% vs. 43%, p = 0.071) compared to those receiving aromatase inhibitors (AIs). Here, CYP19A1 is linked to neutropenia.